Bortezomib potentially inhibits cellular growth of vascular endothelial cells through suppression of G2/M transition

Cancer Science

Volumn 101, Issue 6, 2010, Pages 1403-1408

  Tamura, Daisuke ^a,b   Arao, Tokuzo ^a   Tanaka, Kaoru ^a   Kaneda, Hiroyasu ^a   Matsumoto, Kazuko ^a   Kudo, Kanae ^a   Aomatsu, Keiichi ^a   Fujita, Yoshihiko ^a   Watanabe, Takashi ^c   Saijo, Nagahiro ^c   Kotani, Yoshikazu ^b   Nishimura, Yoshihiro ^b   Nishio, Kazuto ^a  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CYCLIN B1; CYCLIN DEPENDENT KINASE 1; PACLITAXEL; VASCULOTROPIN RECEPTOR 2;

APOPTOSIS; ARTICLE; BLOOD VESSEL PERMEABILITY; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL GROWTH; ENDOTHELIUM CELL; GROWTH INHIBITION; PRIORITY JOURNAL; UBIQUITINATION; VASCULAR ENDOTHELIUM;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BORONIC ACIDS; CAPILLARY PERMEABILITY; CELL DIVISION; CELL PROLIFERATION; CELLS, CULTURED; CYCLIN B; ENDOTHELIAL CELLS; G2 PHASE; HUMANS; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77954169427     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2010.01544.x     Document Type: Article

References (28)

1. Ling YH, Liebes L, Jiang JD. Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines. Clin Cancer Res 2003, 9:1145-54.
2. Hochstrasser M. Ubiquitin, proteasomes, and the regulation of intracellular protein degradation. Curr Opin Cell Biol 1995, 7:215-23.
3. Jentsch S, Schlenker S. Selective protein degradation: a journey's end within the proteasome. Cell 1995, 82:881-4.
4. Hershko A, Ciechanover A. The ubiquitin system. Annu Rev Biochem 1998, 67:425-79.
5. Desai SD, Liu LF, Vazquez-Abad D, D'Arpa P. Ubiquitin-dependent destruction of topoisomerase I is stimulated by the antitumor drug camptothecin. J Biol Chem 1997, 272:24159-64.
6. Ciechanover A, DiGiuseppe JA, Bercovich B. Degradation of nuclear oncoproteins by the ubiquitin system in vitro. Proc Natl Acad Sci U S A 1991, 88:139-43.
7. Treier M, Staszewski LM, Bohmann D. Ubiquitin-dependent c-Jun degradation in vivo is mediated by the delta domain. Cell 1994, 78:787-98.
8. Grimm LM, Goldberg AL, Poirier GG, Schwartz LM, Osborne BA. Proteasomes play an essential role in thymocyte apoptosis. EMBO J 1996, 15:3835-44.
9. Roccaro AM, Hideshima T, Raje N. Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. Cancer Res 2006, 66:184-91.
10. Rajkumar SV, Richardson PG, Hideshima T, Anderson KC. Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol 2005, 23:630-9.
11. Mani A, Gelmann EP. The ubiquitin-proteasome pathway and its role in cancer. J Clin Oncol 2005, 23:4776-89.
12. Genini D, Carbone GM, Catapano CV. Multiple Interactions between Peroxisome Proliferators-Activated Receptors and the Ubiquitin-Proteasome System and Implications for Cancer Pathogenesis. PPAR Res 2008, 2008.
13. APEX (Assessment of Proteasome inhibition for Extending remissions) trial: phase III randomized, multicenter, placebo-controlled trial to evaluate the efficacy and safety of bortezomib versus dexamethasone in patients with recurrent or treatment-resistant multiple myeloma. Clin Adv Hematol Oncol 2003, 1.
14. Jung L, Holle L, Dalton WS. Discovery, Development, and clinical applications of bortezomib. Oncology (Williston Park) 2004, 18:4-13.
15. Richardson PG, Sonneveld P, Schuster MW. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005, 352:2487-98.
16. Pham LV, Tamayo AT, Yoshimura LC, Lo P, Ford RJ. Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis. J Immunol 2003, 171:88-95.
17. Hideshima T, Richardson P, Chauhan D. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001, 61:3071-6.
18. Strauss SJ, Higginbottom K, Juliger S. The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines. Cancer Res 2007, 67:2783-90.
19. Hayashi T, Hideshima T, Anderson KC. Novel therapies for multiple myeloma. Br J Haematol 2003, 120:10-7.
20. Hideshima T, Chauhan D, Podar K, Schlossman RL, Richardson P, Anderson KC. Novel therapies targeting the myeloma cell and its bone marrow microenvironment. Semin Oncol 2001, 28:607-12.
21. Podar K, Shringarpure R, Tai YT. Caveolin-1 is required for vascular endothelial growth factor-triggered multiple myeloma cell migration and is targeted by bortezomib. Cancer Res 2004, 64:7500-6.
22. Takeda M, Arao T, Yokote H. AZD2171 shows potent antitumor activity against gastric cancer over-expressing fibroblast growth factor receptor 2/keratinocyte growth factor receptor. Clin Cancer Res 2007, 13:3051-7.
23. Matsumoto K, Arao T, Tanaka K. mTOR signal and hypoxia-inducible factor-1 alpha regulate CD133 expression in cancer cells. Cancer Res 2009, 69:7160-4.
24. Schwartz EL. Antivascular actions of microtubule-binding drugs. Clin Cancer Res 2009, 15:2594-601.
25. Leonard JP, Furman RR, Coleman M. Proteasome inhibition with bortezomib: a new therapeutic strategy for non-Hodgkin's lymphoma. Int J Cancer 2006, 119:971-9.
26. Lippert JW. Vascular disrupting agents. Bioorg Med Chem 2007, 15:605-15.
27. Tozer GM, Kanthou C, Baguley BC. Disrupting tumour blood vessels. Nat Rev Cancer 2005, 5:423-35.
28. Siemann DW, Bibby MC, Dark GG. Differentiation and definition of vascular-targeted therapies. Clin Cancer Res 2005, 11:416-20.